Amarin Highlights Key Data on Mechanisms of Action for IPE at ESC 2025
ByAinvest
Sunday, Aug 31, 2025 8:31 am ET1min read
AMRN--
Amarin Corporation presented in vitro data at the European Society of Cardiology Congress 2025 that highlights the mechanism of action for its drug VASCEPA/VAZKEPA. The data shows that eicosapentaenoic acid (EPA) modulates inflammasome activation in monocyte-derived macrophages and inhibits lipoprotein(a) oxidation, which may contribute to reducing inflammation and cardiovascular risk. The findings provide additional insight into the mechanisms of action for VASCEPA/VAZKEPA and its potential impact on reducing cardiovascular events in at-risk patients.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet